Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: Results of a phase I trial

Journal of Clinical Oncology

Volumn 22, Issue 13, 2004, Pages 2540-2545

  Kent, Elizabeth ^a   Sandler, Howard ^a   Montie, James ^a   Lee, Cheryl ^a   Herman, Joseph ^a   Esper, Peg ^a   Fardig, Judith ^a   Smith, David C ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG TOLERABILITY; EDEMA; HUMAN; MALAISE; MAXIMUM TOLERATED DOSE; MULTIMODALITY CANCER THERAPY; ORGAN PRESERVATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TRANSURETHRAL RESECTION; AGED; BLADDER TUMOR; FEMALE; MALE; MIDDLE AGED; PATHOLOGY;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; URINARY BLADDER NEOPLASMS;

EID: 4344633285     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.10.070     Document Type: Article

References (43)

1. Jemal A, Thomas A, Murray T, et al: Cancer statistics, 2002. CA Cancer J Clin 52:23-47, 2002
2. Shelley MD, Barber J, Wilt T, et al: Surgery versus radiotherapy for invasive bladder cancer. Cochrane Database Syst Rev, 2002 (CD002079)
3. Stein JP, Lieskovsky G, Cote R, et al: Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 19:666-675, 2001
4. Gschwend JE, Fair WR, Vieweg J: Radical cystectomy for invasive bladder cancer: Contemporary results and remaining controversies. Eur Urol 38:121-130, 2000
5. Quilty PM, Duncan W: Primary radical radiotherapy for T3 transitional cell cancer of the bladder: An analysis of survival and control. Int J Radiat Oncol Biol Phys 12:853-860, 1986
6. Wallace DM, Bloom HJ: The management of deeply infiltrating (T3) bladder carcinoma: Controlled trial of radical radiotherapy versus preoperative radiotherapy and radical cystectomy (first report). Br J Urol 48:587-594, 1976
7. Goffinet DR, Schneider MJ, Glatstein EJ, et al: Bladder cancer: Results of radiation therapy in 384 patients. Radiology 117:149-153, 1975
8. Srougi M, Simon SD: Primary methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and bladder preservation in locally invasive bladder cancer: A 5-year followup. J Urol 151:593-597, 1994
9. Sternberg CN, Raghaven D, Ohi Y, et al: Neoadjuvant and adjuvant chemotherapy in advanced disease - what are the effects on survival and prognosis? Int J Urol 2:76-88, 1995 (suppl 2)
10. Angulo JC, Sanchez-Chapado M, Lopez JI, et al: Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: Multivariate analysis on prognostic factors. J Urol 155:1897-1902, 1996
11. Tester W, Porter A, Asbell S, et al: Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 25:783-790, 1993
12. Dunst J, Sauer R, Schrott KM, et al: Organ-sparing treatment of advanced bladder cancer: A 10-year experience. Int J Radiat Oncol Biol Phys 30:261-266, 1994
13. Kaufman DS, Winter KA, Shipley WU, et al: The initial results in muscle-invading bladder cancer of RTOG 95-06: Phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 5:471-476, 2000
14. Housset M, Maulard C, Chretien Y, et al: Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: A prospective study. J Clin Oncol 11:2150-2157, 1993
15. Given RW, Parsons JT, McCarley D, et al: Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: A five-year follow-up. Urology 46:499-504, 1995
16. Tester W, Caplan R, Heaney J, et al: Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 14:119-126, 1996
17. Shipley WU, Winter KA, Kaufman DS, et al: Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 16:3576-3583, 1998
18. Shipley WU, Kaufman DS, Heney NM, et al: An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy. J Urol 162:445-450; discussion 450-1, 1999
19. Kachnic LA, Kaufman DS, Heney NM, et al: Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 15:1022-1029, 1997
20. Rodel C, Grabenbauer GG, Kuhn R, et al: Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 20:3061-3071, 2002
21. Stadler WM, Kuzel T, Roth B, et al: Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15:3394-3398, 1997
22. Moore MJ, Tannock IF, Ernst DS, et al: Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15:3441-3445, 1997
23. Lorusso V, Pollera CF, Antimi M, et al: A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Cooperative Group on Bladder Cancer. Eur J Cancer 34:1208-1212, 1998
24. Sternberg CN, Yagoda A, Scher HI, et al: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139:461-469, 1988
25. Moore MJ, Winquist EW, Murray N, et al: Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17:2876-2881, 1999
26. Kaufman D, Raghavan D, Carducci M, et al: Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18:1921-1927, 2000
27. Hussain M, Vaishampayan U, Du W, et al: Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 19:2527-2533, 2001
28. Shewach DS, Lawrence TS: Radiosensitization of human solid tumor cell lines with gemcitabine. Semin Oncol 23:65-71, 1996
29. Latz D, Fleckenstein K, Eble M, et al: Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys 41:875382, 1998
30. Heinemann V, Xu YZ, Chubb S, et al: Inhibition of Ribonucleotide Reduction in Ccrf-Cem Cells By 2′,2′-Difluorodeoxycytidine. Mol Pharmacol 38:567-572, 1990
31. Shewach DS, Hahn TM, Chang E, et al: Metabolism of 2′,2′- difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 54:3218-3223, 1994
32. Eisbruch A, Shewach DS, Bradford CR, et al: Radiation concurrent with gemcitabine for locally advanced head and neck cancer: A phase I trial and intracellular drug incorporation study. J Clin Oncol 19:792-799, 2001
33. Gregor A: Gemcitabine plus radiotherapy for non-small cell lung cancer. Semin Oncol 24:58-39-58-11, 1997 (3 suppl 8)
34. Jassem J: Combined chemotherapy and radiation in locally advanced non-small-cell lung cancer. Lancet Oncol 2:335-342, 2001
35. Shewach DS, Lawrence TS: Gemcitabine and radiosensitization in human tumor cells. Invest New Drugs 14:257-263, 1996
36. Lawrence TS, Chang EY, Hahn TM, et al: Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′- difluoro-2′-deoxycytidine (Gemcitabine). Clin Cancer Res 3:777-782, 1997
37. Blackstock AW, Bernard SA, Richards F, et al: Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 17:2208-2212, 1999
38. Pipas JM, Mitchell SE, Barth RJ Jr., et al: Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 50:1317-1322, 2001
39. Epelbaum R, Rosenblatt E, Nasrallah S, et al: Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol 81:138-143, 2002
40. Wolff RA, Evans DB, Gravel DM, et al: Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 7:2246-2253, 2001
41. Crane CH, Janjan NA, Evans DB, et al: Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol 29:9-18, 2001
42. Poggi MM, Kroog GS, Russo A, et al: Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 54:670-676, 2002
43. McGinn CJ, Zalupski MM, Shureiqi I, et al: Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19:4202-4208, 2001